Structure Elucidation of Novel Metabolites of Gemfibrozil in Dog: Conjugation Reaction of Conjugated Metabolites

  • ISHIKAWA Minoru
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd. Department of Biotechnology, Faculty of Engineering, Tottori University
  • HONDA Tomoyo
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd.
  • YOSHII Hidefumi
    Department of Biotechnology, Faculty of Engineering, Tottori University
  • IKEDA Toshihiko
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd.
  • IWABUCHI Haruo
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd.

この論文をさがす

抄録

After oral administration of 14C-labeled gemfibrozil to male dogs, ten metabolites of gemfibrozil, designated as dog metabolite (DM)-1, DM-2, DM-3, DM-4, DM-5-1, DM-5-2, DM-6, DM-7, DM-8, and DM-9, were detected in the urine. Structural analysis of these metabolites by mass spectrometry and tandem mass spectrometry in various ionization modes demonstrated that DM-1, DM-2, DM-3, DM-4, DM-5-1, DM-5-2, and DM-6 were previously unreported metabolites of gemfibrozil. With the exception of DM-8 and DM-9, the gemfibrozil metabolites in dog urine were conjugated metabolites produced by glucuronidation at the carboxylic acid group and the phenolic hydroxyl group generated metabolically or by sulfo-conjugation at the phenolic hydroxyl group. Interestingly, DM-1 and DM-2 were demonstrated to be unique, doubly conjugated forms of DM-9. In DM-1, glucuronidation had occurred at both the carboxylic acid group and phenolic hydroxyl group. In DM-2, sulfo-conjugation at the phenolic hydroxyl group and glucuronidation at the carboxylic acid group had occurred. Therefore, the dogs were found to possess enzymatic mechanisms that glucuronidate or sulfo-conjugate already conjugated metabolites, converting water-soluble metabolites to hydrophilic metabolites.

収録刊行物

  • 質量分析

    質量分析 52 (1), 21-28, 2004

    一般社団法人 日本質量分析学会

被引用文献 (1)*注記

もっと見る

参考文献 (29)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ